AliveCor incorporates AI into consumer diagnostics offering
MOUNTAIN VIEW, Calif. – AliveCor on Thursday announced the U.S. release of Kardia Pro, an artificial intelligence-enabled platform for doctors to monitor patients for the early detection of atrial fibrillation.
“To manage heart disease and stroke risk, leading cardiologists want to see more than just ECGs from their patients,” stated Vic Gundotra, AliveCor CEO. “Kardia Pro tracks important measures of physiology like weight, activity and blood pressure, and, for the first time, AI technology is used to create a personal heart profile for each user, enabling user identification," he said. "The new platform enables doctors to be better doctors and patients to be more active participants in their own heart health, driving healthcare forward into the 21st century.”
The company also announced $30 million in new funding, led by Omron Healthcare and Mayo Clinic, fueling the company’s mission to improve the quality of care in the fight against heart disease and stroke. AliveCor will use the additional capital to accelerate innovations in heart health and continue the rapid expansion of the business.
“We are establishing new partnerships to redefine the role of technology in heart health as part of our Going for Zero mission," noted Ranndy Kellogg, Omron Healthcare CEO. "Partnering with AliveCor advances our path forward to build robust software programs that play a dynamic role in expanding heart health awareness, transforming the patient and caregiver dynamic and taking real steps toward eliminating heart attack and stroke.”
AliveCor’s AI technology will make it easier for doctors to detect changes early and practice preventative medicine.
Pharmavite launches four new supplements
NORTHRIDGE, Calif. — Pharmavite launched four new products onto retail shelves in March, including two gummy vitamins, an immune-system booster and an omega-3 supplement.
"We strive to develop products that meet consumers' needs, and the breadth of our new product line up this year is no exception to this commitment," stated Tim Toll, chief customer officer at Pharmavite. "As a leading brand in the vitamin and supplement industry, we take pride in developing quality products that help consumers meet their daily nutritional needs."
The new products include:
- Nature Made Omega-3 with Xtra Absorb Technology. This supplement is designed to provide superior absorption of heart healthy omega-3 fatty acids through the company's patented technology. The product's Xtra Absorb Technology creates micro-droplets that enhance the absorption of EPA and DHA omega-3s to provide almost four times better absorption that standard fish oil concentrate;
- Nature Made Immune Care Daily Support. Immune Care charges the body's natural immune defenses through the power of green tea;
- Nature Made Dual Action Digestive Probiotic + Energy B12 Gummies. The gummies, which come in raspberry and cherry flavors, are formulated with probiotics and vitamin B12 to support cellular energy production; and
- Nature Made Adult Gummies for Him Plus Omega-3s. Formulated with the male cosumer in mind, these gummies combine 11 key nutrients of daily nutritional support.
Osato International brings papaya-based immunity booster to U.S.
LOS ANGELES — Osato International recently brought Immun’Âge, a fermented papaya preparation, to the U.S. market. According to Osato, the superfood supplement helps boost the immune system and serves as an antioxidant.
"Many of the chronic ailments afflicting us as we age have multiple origins and a common factor – oxidative stress," noted Pierre Mantello, executive director of the Osato Research Institute. "Immun’Âge is easily ingested and has proven to have remarkable antioxidant and immunostimulating properties."
The process behind Immun’Âge begins on Hawaii's Big Island, where the only non-GMO-certified papayas are grown at the Diamond Head Papay Co., the company reported. The fermentation process takes 10 months.
According to the company, Immun’Âge is a popular food supplement in Italy, with additional distribution across Europe.